Split History
ETFs Holding AGRX »    AGRX Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Agile Therapeutics is a women's healthcare company. Co.'s primary product candidate, Twirla, is a once-weekly prescription combination hormonal contraceptive patch. It delivers a dose of estrogen that is consistent with commonly prescribed combined hormonal contraceptives. Co.'s pipeline consists of two classes of product candidates: Co.'s potential product pipeline consists of two types of product candidates: a progestin-only contraceptive patch and potential Twirla line extensions. These potential product candidates are designed to address market needs and provide additional non-daily contraceptive options. Including AG200-15 Extended Regimen, AG200-SmP, and AG200-15 ER SmP. According to our AGRX split history records, Agile Therapeutics has had 1 split.
AGRX split history picture
Agile Therapeutics (AGRX) has 1 split in our AGRX split history database. The split for AGRX took place on April 27, 2022. This was a 1 for 40 reverse split, meaning for each 40 shares of AGRX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 25 share position following the split.

When a company such as Agile Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the AGRX split history from start to finish, an original position size of 1000 shares would have turned into 25 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Agile Therapeutics shares, starting with a $10,000 purchase of AGRX, presented on a split-history-adjusted basis factoring in the complete AGRX split history. AGRX split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 05/27/2014
End date: 01/27/2023
Start price/share: $222.00
End price/share: $0.27
Dividends collected/share: $0.00
Total return: -99.88%
Average Annual Total Return: -53.88%
Starting investment: $10,000.00
Ending investment: $12.12
Years: 8.68
Date Ratio
04/27/20221 for 40
AGRX is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

AGTI Split History
AHPI Split History
AIKI Split History
AIMT Split History
AIQ Split History
AIRM Split History
AKER Split History
ALBO Split History
ALBT Split History
ALC Split History

Also explore: AGRX shares outstanding history

Email EnvelopeFree AGRX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Galway Metals Inc. (GWM.CA)
Lannett Company, Inc. (LCI)
Reed's, Inc. (REED)
Phio Pharmaceuticals Corp. (PHIO)
Swvl Holdings Corp (SWVL)
Sientra, Inc. (SIEN)
Eargo, Inc. (EAR)
Alterity Therapeutics Limited (ATHE)
Aytu BioPharma, Inc. (AYTU)
OpGen, Inc. (OPGN)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

AGRX Insider Buying

AGRX Split History | www.SplitHistory.com | Copyright © 2013 - 2023, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.